REVBW · Insider Trading
Revelation Biosciences, Inc. Warrant
Every open-market purchase and sale reported by REVBW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-01 | James Rolke | Chief Executive Officer | F | −10,115 | −$11.43K |
| 2026-05-01 | Chester Stanley Zygmont III | Chief Financial Officer | F | −13,285 | −$14.61K |
| 2026-02-05 | Jennifer Carver | Director | F | −1,661 | −$3.11K |
| 2026-02-05 | Chester Stanley Zygmont III | Chief Financial Officer | F | −13,100 | −$21.61K |
| 2026-02-05 | James Rolke | Chief Executive Officer | F | −8,521 | −$15.85K |
| 2026-02-05 | Lakhmir S Chawla | Director | F | −2,261 | −$4.18K |
| 2026-02-05 | Jess Roper | Director | F | −1,591 | −$2.94K |
| 2026-01-12 | Jess Roper | Director | A | +41,981 | +$37.78K |
| 2026-01-12 | Chester Stanley Zygmont III | Chief Financial Officer | A | +78,145 | +$70.33K |
| 2026-01-12 | James Rolke | Chief Executive Officer | A | +532,829 | +$479.55K |
| 2026-01-12 | Jennifer Carver | Director | A | +41,981 | +$37.78K |
| 2026-01-12 | Lakhmir S Chawla | Director | A | +41,981 | +$37.78K |
| 2025-10-31 | James Rolke | Chief Executive Officer | A | +390,614 | +$499.99K |
| 2025-10-31 | Chester Stanley Zygmont III | Chief Financial Officer | A | +390,614 | +$499.99K |
| 2025-10-31 | Jennifer Carver | Director | A | +15,625 | +$20.00K |
| 2025-10-31 | Lakhmir S Chawla | Director | A | +15,625 | +$20.00K |
| 2025-10-31 | Jess Roper | Director | A | +15,625 | +$20.00K |
| 2025-02-13 | Jess Roper | Director | A | +181 | +$700 |
| 2025-02-13 | Chester Stanley Zygmont III | Chief Financial Officer | A | +15,048 | +$58.24K |
| 2025-02-13 | Jennifer Carver | Director | A | +181 | +$700 |
| 2025-02-13 | Lakhmir S Chawla | Director | A | +181 | +$700 |
| 2025-02-13 | James Rolke | Chief Executive Officer | A | +30,095 | +$116.47K |
| 2025-02-13 | George F Tidmarsh | Director | A | +181 | +$700 |
| 2023-12-12 | George F Tidmarsh | Director | Sell | −27,771 | −$14.44K |
| 2023-10-18 | George F Tidmarsh | Director | Sell | −1,845 | −$1.20K |
| 2023-10-17 | George F Tidmarsh | Director | Sell | −10,957 | −$7.24K |
| 2023-10-02 | George F Tidmarsh | Director | Sell | −1,429 | −$986 |
| 2023-09-18 | George F Tidmarsh | Director | Sell | −25,500 | −$18.89K |
| 2023-04-19 | George F Tidmarsh | Director | Buy | +51,500 | +$59.74K |
| 2023-04-18 | George F Tidmarsh | Director | A | +6,356 deriv. | — |
| 2023-04-18 | Curt H LaBelle | Director | A | +6,356 deriv. | — |
| 2023-04-18 | Jennifer Carver | Director | A | +6,356 deriv. | — |
| 2023-04-18 | Jess Roper | Director | A | +6,356 deriv. | — |
| 2023-02-28 | James Rolke | Chief Executive Officer | A | +2,542 deriv. | — |
| 2023-02-28 | Chester Stanley Zygmont III | Chief Financial Officer | A | +611 deriv. | — |
| 2022-02-28 | George F Tidmarsh | Director | Buy | +20,000 | +$32.00K |
| 2022-02-10 | George F Tidmarsh | Director | Buy | +31,000 | +$79.14K |
| 2022-02-09 | George F Tidmarsh | Director | Buy | +52,000 | +$132.94K |
| 2022-02-08 | George F Tidmarsh | Director | Buy | +50,000 | +$128.04K |
| 2022-01-11 | Lawrence Feis | 10%+ Owner | J | −731,950 | −$7.47M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| James Rolke | Chief Executive Officer | 214,738 | $795 |
| Chester Stanley Zygmont III | Chief Financial Officer | 92,063 | $341 |
| Jess Roper | Director | 12,828 | $47 |
| Jennifer Carver | Director | 12,758 | $47 |
| Lakhmir S Chawla | Director | 12,158 | $45 |
| George F Tidmarsh | Director | 268 | $1 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the REVBW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.